Found 1075 with Last Name = 'yu' and Initial = 'pb' 
3D Structure (crystal)
Affinity DataIC50: <1nMAssay Description:In this reporter gene cell based ALK2 and TGFβ assay, the C2Cl2 cell line was employed for the measurement of ALK2 activity, using a BRE-Luc SMA...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase receptor R3(Mus musculus)
Massachusetts Institute Of Technology
Massachusetts Institute Of Technology
Affinity DataIC50: 2nMAssay Description:In this reporter gene cell based ALK2 and TGFβ assay, the C2Cl2 cell line was employed for the measurement of ALK2 activity, using a BRE-Luc SMA...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase receptor R3(Mus musculus)
Massachusetts Institute Of Technology
Massachusetts Institute Of Technology
Affinity DataIC50: 3nMAssay Description:In this reporter gene cell based ALK2 and TGFβ assay, the C2Cl2 cell line was employed for the measurement of ALK2 activity, using a BRE-Luc SMA...More data for this Ligand-Target Pair
Affinity DataIC50: 3nMAssay Description:In this reporter gene cell based ALK2 and TGFβ assay, the C2Cl2 cell line was employed for the measurement of ALK2 activity, using a BRE-Luc SMA...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase receptor R3(Mus musculus)
Massachusetts Institute Of Technology
Massachusetts Institute Of Technology
Affinity DataIC50: 4nMAssay Description:In this reporter gene cell based ALK2 and TGFβ assay, the C2Cl2 cell line was employed for the measurement of ALK2 activity, using a BRE-Luc SMA...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase receptor R3(Homo sapiens (Human))
The Brigham And Women'S Hospital
US Patent
The Brigham And Women'S Hospital
US Patent
Affinity DataIC50: 4nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase receptor R3(Homo sapiens (Human))
The Brigham And Women'S Hospital
US Patent
The Brigham And Women'S Hospital
US Patent
Affinity DataIC50: 4nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase receptor R3(Homo sapiens (Human))
The Brigham And Women'S Hospital
US Patent
The Brigham And Women'S Hospital
US Patent
Affinity DataIC50: 4nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
Affinity DataIC50: 4nMAssay Description:Inhibition of BMP6-induced BMP receptor type 1 ALK2 in mouse C2C12 cells after 30 mins by luciferase reporter gene assayMore data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase receptor R3(Homo sapiens (Human))
The Brigham And Women'S Hospital
US Patent
The Brigham And Women'S Hospital
US Patent
Affinity DataIC50: 4nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
Affinity DataIC50: 4.90nMAssay Description:Inhibition of BMP4 (unknown origin)-induced phosphorylation of SMAD 1/5/8 by cytoblot cellular ELISAMore data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:In this reporter gene cell based ALK2 and TGFβ assay, the C2Cl2 cell line was employed for the measurement of ALK2 activity, using a BRE-Luc SMA...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:Inhibition of BMP4 (unknown origin)-induced phosphorylation of SMAD 1/5/8 by cytoblot cellular ELISAMore data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase receptor R3(Homo sapiens (Human))
The Brigham And Women'S Hospital
US Patent
The Brigham And Women'S Hospital
US Patent
Affinity DataIC50: 5.80nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase receptor R3(Homo sapiens (Human))
The Brigham And Women'S Hospital
US Patent
The Brigham And Women'S Hospital
US Patent
Affinity DataIC50: 5.80nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Affinity DataIC50: 6nMAssay Description:Inhibition of human recombinant human ALK2 kinase after 45 mins by liquid scintillation counting in presence of ATP [gamma-32P]More data for this Ligand-Target Pair
Affinity DataIC50: 6nMAssay Description:In this reporter gene cell based ALK2 and TGFβ assay, the C2Cl2 cell line was employed for the measurement of ALK2 activity, using a BRE-Luc SMA...More data for this Ligand-Target Pair
Affinity DataIC50: 6nMAssay Description:In this reporter gene cell based ALK2 and TGFβ assay, the C2Cl2 cell line was employed for the measurement of ALK2 activity, using a BRE-Luc SMA...More data for this Ligand-Target Pair
Affinity DataIC50: 6nMAssay Description:Inhibition of BMP6-induced BMP receptor type 1 ALK2 in mouse C2C12 cells after 30 mins by luciferase reporter gene assayMore data for this Ligand-Target Pair
Affinity DataIC50: 6nMAssay Description:In this reporter gene cell based ALK2 and TGFβ assay, the C2Cl2 cell line was employed for the measurement of ALK2 activity, using a BRE-Luc SMA...More data for this Ligand-Target Pair
TargetBone morphogenetic protein receptor type-1A(Homo sapiens (Human))
The Brigham And Women'S Hospital
US Patent
The Brigham And Women'S Hospital
US Patent
Affinity DataIC50: 6.5nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetBone morphogenetic protein receptor type-1A(Homo sapiens (Human))
The Brigham And Women'S Hospital
US Patent
The Brigham And Women'S Hospital
US Patent
Affinity DataIC50: 6.5nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Affinity DataIC50: 7nMAssay Description:In this reporter gene cell based ALK2 and TGFβ assay, the C2Cl2 cell line was employed for the measurement of ALK2 activity, using a BRE-Luc SMA...More data for this Ligand-Target Pair
TargetBone morphogenetic protein receptor type-1A(Homo sapiens (Human))
The Brigham And Women'S Hospital
US Patent
The Brigham And Women'S Hospital
US Patent
Affinity DataIC50: 7nMAssay Description:Inhibition of ALK3 (unknown origin) using Ulight topo IIa (Thr 1342) peptide as substrate preincubated for 10 mins followed by substrate addition and...More data for this Ligand-Target Pair
Affinity DataIC50: 7.70nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Affinity DataIC50: 7.70nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
Affinity DataIC50: 8nMAssay Description:In this reporter gene cell based ALK2 and TGFβ assay, the C2Cl2 cell line was employed for the measurement of ALK2 activity, using a BRE-Luc SMA...More data for this Ligand-Target Pair
Affinity DataIC50: 8nMAssay Description:In this reporter gene cell based ALK2 and TGFβ assay, the C2Cl2 cell line was employed for the measurement of ALK2 activity, using a BRE-Luc SMA...More data for this Ligand-Target Pair
Affinity DataIC50: 8nMAssay Description:In this reporter gene cell based ALK2 and TGFβ assay, the C2Cl2 cell line was employed for the measurement of ALK2 activity, using a BRE-Luc SMA...More data for this Ligand-Target Pair
Affinity DataIC50: 8nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
Affinity DataIC50: 8nMAssay Description:In this reporter gene cell based ALK2 and TGFβ assay, the C2Cl2 cell line was employed for the measurement of ALK2 activity, using a BRE-Luc SMA...More data for this Ligand-Target Pair
Affinity DataIC50: 8nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Affinity DataIC50: 8.60nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
Affinity DataIC50: 8.60nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Affinity DataIC50: 9nMAssay Description:In this reporter gene cell based ALK2 and TGFβ assay, the C2Cl2 cell line was employed for the measurement of ALK2 activity, using a BRE-Luc SMA...More data for this Ligand-Target Pair
Affinity DataIC50: 9nMAssay Description:In this reporter gene cell based ALK2 and TGFβ assay, the C2Cl2 cell line was employed for the measurement of ALK2 activity, using a BRE-Luc SMA...More data for this Ligand-Target Pair
Affinity DataIC50: 9nMAssay Description:In this reporter gene cell based ALK2 and TGFβ assay, the C2Cl2 cell line was employed for the measurement of ALK2 activity, using a BRE-Luc SMA...More data for this Ligand-Target Pair
Affinity DataIC50: 9nMAssay Description:Inhibition of ALK2 (unknown origin) using Ulight topo IIa (Thr 1342) peptide as substrate preincubated for 10 mins followed by substrate addition and...More data for this Ligand-Target Pair
Affinity DataIC50: 9nMAssay Description:Inhibition of ALK2 (unknown origin) using Ulight topo IIa (Thr 1342) peptide as substrate preincubated for 10 mins followed by substrate addition and...More data for this Ligand-Target Pair
Affinity DataIC50: 9nMAssay Description:In this reporter gene cell based ALK2 and TGFβ assay, the C2Cl2 cell line was employed for the measurement of ALK2 activity, using a BRE-Luc SMA...More data for this Ligand-Target Pair
TargetBone morphogenetic protein receptor type-1A(Homo sapiens (Human))
The Brigham And Women'S Hospital
US Patent
The Brigham And Women'S Hospital
US Patent
Affinity DataIC50: 9.10nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
TargetBone morphogenetic protein receptor type-1A(Homo sapiens (Human))
The Brigham And Women'S Hospital
US Patent
The Brigham And Women'S Hospital
US Patent
Affinity DataIC50: 9.10nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetBone morphogenetic protein receptor type-1A(Homo sapiens (Human))
The Brigham And Women'S Hospital
US Patent
The Brigham And Women'S Hospital
US Patent
Affinity DataIC50: 9.20nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
